Tumor-associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to...

Area of Science:

• Immunology
• Cancer Biology
• Immunotherapy

Background:

• Immune checkpoint blockers (ICB) targeting the PD-1/PD-L1 axis are vital cancer treatments.
• Therapeutic resistance is common due to complex immunosuppressive mechanisms within the tumor microenvironment.
• The role of natural killer (NK) cells in T-cell dysfunction and ICB efficacy is debated.

Purpose of the Study:

• To investigate the impact of NK cells on CD8+ T-cell differentiation and ICB sensitivity.
• To elucidate the mechanisms by which NK cells may impede anti-tumor immune responses.
• To explore the clinical relevance of NK cell frequency in predicting ICB response.

Main Methods:

• Genetic and antibody-mediated depletion of NK cells in preclinical cancer models.
• Analysis of CD8+ T-cell differentiation markers and gene expression.
• Assessment of cytokine competition for IFNα and IL-2.
• Correlation analysis of NK cell frequency with clinical response data in cancer patients.

Main Results:

• A subset of tumor-associated NK cells negatively impacts ICB sensitivity.
• NK cells impede CD8+ T-cell differentiation by competing for essential cytokines (IFNα, IL-2).
• Reduced frequencies of NK cells are associated with improved clinical responses to ICB therapy.

Conclusions:

• Tumor-infiltrating NK cells can exert immunosuppressive functions, hindering CD8+ T-cell-mediated anti-tumor immunity.
• Targeting regulatory NK cells may represent a strategy to enhance CD8+ T-cell-centered immunotherapies.
• NK cell frequency serves as a potential biomarker for predicting ICB efficacy.